Barclays Cuts Estimates on Par Pharmaceutical (PRX); Removing Lovaza Contribution From Model

Barclays maintains an 'Equalweight' on Par Pharmaceutical (NYSE: PRX) price target of $35.00.

Analyst, Douglas D. Tsao, said, "We our removing a generic Lovaza contribution from our 2012-2016 estimates and now assume no contribution until patent expiry in 2017. Our revised EPS estimates are as follows: 2012 - $3.70 vs previous $3.85; 2013 - $2.92 vs previous $3.26; 2014 - $3.29 vs previous $4.24; 2015 - $3.46 vs previous $3.91; 2016 - $4.80 vs previous $5.25."

For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.

Shares of Par Pharmaceutical closed at $37.01 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)